VYNE Therapeutics Inc.
NASDAQ: VYNE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David T. Domzalski
- Employees
- 13
- Headquarters
- Bridgewater, United States
- IPO year
- 2018
- Market cap
- $10.8M
- Website
- https://www.vynetherapeutics.com
Loading VYNE…
Loading profile data…Frequently asked questions about VYNE
What does VYNE Therapeutics Inc. (VYNE) do?
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candida...
Where does VYNE trade?
VYNE Therapeutics Inc. (VYNE) trades on the NASDAQ Global Select.
What sector is VYNE in?
VYNE Therapeutics Inc. (VYNE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of VYNE Therapeutics Inc.?
David T. Domzalski is the chief executive officer of VYNE Therapeutics Inc. (VYNE).
Where is VYNE Therapeutics Inc. headquartered?
VYNE Therapeutics Inc. is headquartered in United States.
Does VYNE pay a dividend?
VYNE Therapeutics Inc. (VYNE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VYNE go public?
VYNE Therapeutics Inc. (VYNE) completed its initial public offering in 2018.